E. coli alters ribosomes to survive antibiotic treatment
New study shows E. coli resists antibiotics by modifying its ribosome structure, blocking drug binding and enabling growth despite treatment.
List view / Grid view
New study shows E. coli resists antibiotics by modifying its ribosome structure, blocking drug binding and enabling growth despite treatment.
By acquiring Evotec, Halozyme aims to enhance drug discovery and delivery, driving substantial growth in the pharmaceutical sector.
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
A University of Sydney study reveals how DNA origami can build programmable nanostructures, with promising applications in targeted drug delivery and nanorobotics.
CNIC researchers have identified a mechanism in fat cells that helps them safely store excess fat, offering new insights for combating obesity and related metabolic diseases.
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
Metrion Biosciences is set to accelerate its global expansion and enhance its leadership in ion channel drug discovery services.
A promising new inhaled therapy is progressing in Phase 2 trials, presenting new opportunities for improving cystic fibrosis treatment.
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
New collaboration focuses on transforming academic research into innovative therapies for urgent medical conditions, including cancer and heart disease.
The glaucoma drug methazolamide removed tau build-up and lessened signs of dementia in genetically-engineered zebrafish and mice.
Researchers have uncovered a how INPP4B, alongside PIKfyve and TRPML-1, drives pancreatic cancer metastasis.
Based on MRI scans from 732 prostate cancer patients, the AI model identified the edges of 85 percent of the most radiologically aggressive lesions.
Disrupting F-actin in aged brains restored brain autophagy to youthful levels and reversed some cellular markers of brain ageing.
The findings offer a promising drug target to prevent progression to colon cancer by targeting abnormal cells early on.